AdipoGen Life Sciences

LY2784544

Product Code:
 
SYN-1196
Product Group:
 
Inhibitors and Activators
Regulatory Status:
 
RUO
Shipping:
 
-20°C
1 / 1
Chemical Structure

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
SYN-1196-M100100 mgEnquire
Quantity:
SYN-1196-M0011 mg£115.00
Quantity:
SYN-1196-M0055 mg£197.00
Quantity:
SYN-1196-M01010 mg£303.00
Quantity:
SYN-1196-M05050 mg£1,053.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Alternate Names/Synonyms:
LY-2784544
Appearance:
Solid.
CAS:
1229236-86-5
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
InChiKey:
SQSZANZGUXWJEA-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1229236-86-5. Formula: C23H25ClFN7O. MW: 469.9. LY2784544 is a potent JAK2 inhibitor with IC(50) of 3nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.
Molecular Formula:
C23H25ClFN7O
Molecular Weight:
469.9
Package Type:
Plastic Vial
Product Description:
LY2784544 is a potent JAK2 inhibitor with IC(50) of 3nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F: L. Ma, et al.; Blood Cancer J. 3, e109 (2013)